Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.
GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus ... “Efforts to make insulin more accessible have been at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback